AmerisourceBergen Structures Operating Model and Executive Leadership Team to Offer a More Cohesive and Unified Customer Experience, Enhance Growth and Drive Long-Term Value

Expertise and Services Combined into New “Pharmaceutical Distribution
and Strategic Global Sourcing” and “Global Commercialization Services
and Animal Health” Groups

VALLEY FORGE, Pa.–(BUSINESS WIRE)–AmerisourceBergen (NYSE: ABC) today announced a new organizational
structure designed to further align the organization to its customer
needs in a more seamless and unified way, while supporting corporate
strategy and accelerating growth. The Company’s customer-facing
offerings will now be aligned under two groups:

  • Pharmaceutical Distribution and Strategic Global Sourcing
    Will be led by Group President Robert P. Mauch, Pharm.D., Ph.D., and
    includes the Company’s services to retail chain and independent
    pharmacies, health systems, physician practices and alternate care
    sites as well as AmerisourceBergen’s sourcing, repackaging and
    specialty pharmacy capabilities. Peyton Howell will assume a new role
    as President, Health Systems, Physician Practices and Strategic Health
    Solutions
  • Global Commercialization Services and Animal Health – Will be
    led by Group President James F. Cleary, Jr., and includes the
    Company’s solutions for product commercialization and patient access,
    as well as international development and animal health

“AmerisourceBergen has assembled and built best-in-class capabilities to
support every stage of pharmaceutical care, with the goal of ensuring
access to medicines that create healthier futures for patients,” said
Steven H. Collis, Chairman, President and Chief Executive Officer of
AmerisourceBergen. “This strategy has served as the engine of
AmerisourceBergen’s success and we are now evolving our organization to
capitalize on our unique portfolio of services. Our vision is to
accelerate AmerisourceBergen’s corporate growth by further aligning our
operating model to the dynamic customer needs in the health and
pharmaceutical industry.”

For financial reporting purposes, AmerisourceBergen operations will
continue to be comprised of the Pharmaceutical Distribution Services
reportable segment and Other.

AmerisourceBergen has also formed a new management committee to enable
quicker, cross-functional decision-making. This senior executive group
includes:

  • Steven H. Collis, Chairman, President and Chief Executive Officer
  • John G. Chou, Chief Legal and Business Officer, who will now have
    responsibility for legal and regulatory affairs along with strategy,
    innovation and business development led by Sun Park, Executive Vice
    President, Strategy and Business Development, as well as information
    technology led by Dale Danilewitz, Executive Vice President and Chief
    Information Officer
  • Gina K. Clark, Chief Communications and Administration Officer, who
    will now have responsibility for marketing and communication and
    corporate citizenship and sustainability along with human resources
    led by Kathy H. Gaddes, Executive Vice President and Chief Human
    Resources Officer, government affairs led by Rita Norton, Senior Vice
    President, Government Affairs and Public Policy
  • James F. Cleary, Jr., Group President, Global Commercialization
    Services and Animal Health
  • Tim G. Guttman, Chief Financial Officer
  • Robert P. Mauch, Group President, Pharmaceutical Distribution and
    Strategic Global Sourcing

After 10 years of service with a track record of exceptional integrity,
leadership and performance, James Frary, previously Executive Vice
President and President, AmerisourceBergen Specialty Group (ABSG), has
decided to pursue new opportunities outside of AmerisourceBergen. Frary
will be available to support the organization over the next few months
as he transitions from his role.

“We are better positioned to meet the needs of the marketplace because
of James’ leadership and I’m truly grateful for his guidance and
partnership over the past decade,” said Collis. “We will carry that
industry leadership into our new management committee structure. This
group will be singularly focused on aligning every aspect of
AmerisourceBergen to our purpose, corporate strategy and continued
growth. We believe this next evolution of AmerisourceBergen will enable
the Company to be more nimble and effective, actively supporting our
customers as they grow and unlock the full value of their businesses.”

About AmerisourceBergen

AmerisourceBergen provides pharmaceutical products, value-driving
services and business solutions that improve access to care. Tens of
thousands of healthcare providers, veterinary practices and livestock
producers trust us as their partner in the pharmaceutical supply chain.
Global manufacturers depend on us for services that drive commercial
success for their products. Through our daily work—and powered by our
19,000 associates—we are united in our responsibility to create
healthier futures. AmerisourceBergen is ranked #11 on the Fortune 500,
with more than $145 billion in annual revenue. The company is
headquartered in Valley Forge, Pa. and has a presence in 50+ countries.
Learn more at amerisourcebergen.com.

AmerisourceBergen’s Cautionary Note Regarding Forward-Looking
Statements

Certain of the statements contained in this press release are
“forward-looking statements” within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. Words such as “expect,” “likely,” “outlook,” “forecast,” “would,”
“could,” “should,” “can,” “will,” “project,” “intend,” “plan,”
“continue,” “sustain,” “synergy,” “on track,” “believe,” “seek,”
“estimate,” “anticipate,” “may,” “possible,” “assume,” variations of
such words, and similar expressions are intended to identify such
forward-looking statements. These statements are based on management’s
current expectations and are subject to uncertainty and change in
circumstances. These statements are not guarantees of future performance
and are based on assumptions that could prove incorrect or could cause
actual results to vary materially from those indicated. Among the
factors that could cause actual results to differ materially from those
projected, anticipated, or implied are the following: unfavorable trends
in brand and generic pharmaceutical pricing, including in rate or
frequency of price inflation or deflation; competition and industry
consolidation of both customers and suppliers resulting in increasing
pressure to reduce prices for our products and services; changes in
pharmaceutical market growth rates; substantial defaults in payment,
material reduction in purchases by or the loss, bankruptcy or insolvency
of a major customer; changes to the customer or supplier mix; the
retention of key customer or supplier relationships under less favorable
economics or the adverse resolution of any contract or other dispute
with customers or suppliers; changes to customer or supplier payment
terms; the disruption of AmerisourceBergen’s cash flow and ability to
return value to its stockholders in accordance with its past practices;
risks associated with the strategic, long-term relationship
between Walgreens Boots Alliance, Inc. and AmerisourceBergen, including
with respect to the pharmaceutical distribution agreement and/or the
global sourcing arrangement; changes in the United States healthcare and
regulatory environment, including changes that could impact prescription
drug reimbursement under Medicare and Medicaid; increasing governmental
regulations regarding the pharmaceutical supply channel and
pharmaceutical compounding; federal and state government enforcement
initiatives to detect and prevent suspicious orders of controlled
substances and the diversion of controlled substances; federal and state
prosecution of alleged violations of related laws and regulations, and
any related litigation, including shareholder derivative lawsuits or
other disputes relating to our distribution of controlled substances;
increased federal scrutiny and qui tam litigation for alleged violations
of fraud and abuse laws and regulations and/or any other laws and
regulations governing the marketing, sale, purchase and/or dispensing of
pharmaceutical products or services and any related litigation; material
adverse resolution of pending legal proceedings; declining reimbursement
rates for pharmaceuticals; the acquisition of businesses that do not
perform as expected, or that are difficult to integrate or control,
including the integration of PharMEDium, or the inability to capture all
of the anticipated synergies related thereto; regulatory action in
connection with the production, labeling or packaging of products
compounded by our compounded sterile preparations (CSP) business;
declining economic conditions in the United States and abroad; financial
market volatility and disruption; the loss, bankruptcy or insolvency of
a major supplier; interest rate and foreign currency exchange rate
fluctuations; managing foreign expansion, including non-compliance with
the U.S. Foreign Corrupt Practices Act, anti-bribery laws and economic
sanctions and import laws and regulations; malfunction, failure or
breach of sophisticated information systems to operate as designed;
risks generally associated with data privacy regulation and the
international transfer of personal data; changes in tax laws or
legislative initiatives that could adversely
affect AmerisourceBergen’s tax positions and/or AmerisourceBergen’s tax
liabilities or adverse resolution of challenges
to AmerisourceBergen’s tax positions; natural disasters or other
unexpected events that affect AmerisourceBergen’s operations; the
impairment of goodwill or other intangible assets, resulting in a charge
to earnings; and other economic, business, competitive, legal, tax,
regulatory and/or operational factors
affecting AmerisourceBergen’s business generally. Certain additional
factors that management believes could cause actual outcomes and results
to differ materially from those described in forward-looking statements
are set forth (i) in Item 1A (Risk Factors) in the Company’s Annual
Report on Form 10-K for the fiscal year ended September 30, 2016 and
elsewhere in that report and (ii) in other reports filed by the Company
pursuant to the Securities Exchange Act.

Contacts

AmerisourceBergen Corporation
Media
Gabe
Weissman

Vice President, Communications
610-727-3696
– Office

267-438-7998 – Mobile
gweissman@amerisourcebergen.com
or
Investors
Keri
P. Mattox

Vice President, Corporate & Investor Relations
610-576-7801
– Office

610-427-9280 – Mobile
kmattox@amerisourcebergen.com
or
Bennett
S. Murphy

Director, Corporate & Investor Relations
610-727-3693
– Office

610-209-5691 – Mobile
bmurphy@amerisourcebergen.com